+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Oxandrolone in AIDS-wasting myopathy

Aids 10(14): 1657-1662
Oxandrolone in AIDS-wasting myopathy
Objective: To evaluate oxandrolone, an oral anabolic steroid with potent anabolic activity and minimal androgenic effects, for the treatment of AIDS-associated myopathy and wasting. Methods: In a multicenter, double-blind study, 63 HIV-seropositive men with gt 10% loss of body weight were randomized to receive either placebo, 5 mg/day oxandrolone, or 15 mg/day oxandrolone for 16 weeks. Body weight, neuromuscular evaluation, and measures of well-being were repeatedly assessed. Results: Patients who received 15 mg/day oxandrolone showed weight gain throughout the 16-week treatment period. Overall, the 5 mg/day oxandrolone group maintained their weight gain over the 16-week period, whereas the placebo group showed continual weight loss. At week 16, significantly more patients in the 15 mg/day dose group reported increases in appetite and activity than those receiving placebo. There were no consistent, dose-related, statistically significant differences from baseline in laboratory values or adverse events. Conclusion: Oxandrolone, at a dose of either 5 mg/day or 15 mg/day, in contrast to placebo, had a positive impact on the weight and well-being of HIV-seropositive patients suffering from wasting and weakness. Measurable improvement in muscle strength was not noted at the doses employed in this study. Oxandrolone was well tolerated in all the patients who were enrolled in the study. Based on the results reported here, additional studies using higher doses of oxandrolone seem warranted.

(PDF same-day service: $19.90)

Accession: 002914049

PMID: 8970686

DOI: 10.1097/00002030-199612000-00010

Related references

Oxandrolone as a treatment for aids-related weight loss and wasting. Gastroenterology 112(4 SUPPL ): A1062, 1997

Effects of oxandrolone on body weight and composition in patients with AIDS wasting. AIDS (Hagerstown) 14(Supplement 4): S60, October, 2000

Aids wasting syndrome a treatable myopathy. Neurology 39(3 SUPPL 1): 152, 1989

HIV-associated wasting: brief review and discussion of the impact of oxandrolone. Aids Patient Care and Stds 14(8): 421-425, 2000

Wasting syndrome: oral oxandrolone re-released in U.S. Aids Treatment News: 3-4, 1995

The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 64(7): 725-750, 2004

Oxandrolone, used for treatment of wasting disease in HIV-1-infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in lymphocyte and macrophage cell cultures. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20(3): 215-219, 1999

When why and whom enteral nutritional support in AIDS wasting syndrome of AIDS and in the early HIV disease. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS [Author] Eleventh International Conference on AIDS, Vol One One world: One hope : 308, 1996

Effect of anabolic steroids on HIV-related wasting myopathy. Southern Medical Journal 86(8): 865-866, 1993

Nemaline myopathy with forearm wasting and neurogenic changes on electromyography. Journal of the Neurological Sciences 150(SUPPL ): S122, 1997